- Home
- XPEV vs INCY Comparison
XPEV vs INCY Comparison
Compare XPEV & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XPEV | INCY |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 17.0B |
| IPO Year | 2020 | 1993 |
Fundamental Metrics
Financial Performance| Metric | XPEV | INCY |
|---|---|---|
| Price | $18.97 | $94.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 21 |
| Target Price | $24.90 | ★ $94.94 |
| AVG Volume (30 Days) | ★ 12.2M | 2.1M |
| Earning Date | 11-17-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3878.02 |
| EPS | N/A | ★ 5.90 |
| Revenue | ★ $9,912,782,208.00 | $4,813,105,000.00 |
| Revenue This Year | $96.20 | $19.59 |
| Revenue Next Year | $38.85 | $10.88 |
| P/E Ratio | ★ N/A | $16.02 |
| Revenue Growth | ★ 86.64 | 18.09 |
| 52 Week Low | $11.14 | $53.56 |
| 52 Week High | $28.24 | $109.28 |
Technical Indicators
Market Signals| Indicator | XPEV | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 38.76 | 39.12 |
| Support Level | $18.55 | $94.28 |
| Resistance Level | $20.58 | $96.89 |
| Average True Range (ATR) | 0.63 | 3.13 |
| MACD | -0.16 | -1.42 |
| Stochastic Oscillator | 11.90 | 12.65 |
Price Performance
Historical ComparisonAbout XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.